LOS ANGELES, May 09, 2024 (GLOBE NEWSWIRE) -- NeuroSigma, Inc. today announced its acceptance into the 2024 cohort of the…
TARRYTOWN, New York, May 07, 2024 (GLOBE NEWSWIRE) -- via IBN -- PaxMedica, Inc. (OTC:PXMD), a biopharmaceutical company focused on advancing…
Geneva, Switzerland, May 2, 2024 – STALICLA SA, a late-stage biotechnology company specializing in precision medicine for brain disorders, announces…
TARRYTOWN, New York, April 23, 2024 (GLOBE NEWSWIRE) -- via IBN – PaxMedica Inc. (Nasdaq: PXMD) (the “Company”), a leading…
TARRYTOWN, New York, April 11, 2024 (GLOBE NEWSWIRE) -- via IBN – PaxMedica, Inc. (NASDAQ:PXMD), a biopharmaceutical company focused on…
SAN DIEGO, April 03, 2024 (GLOBE NEWSWIRE) -- Bionano Genomics, Inc. (Nasdaq: BNGO), today announced the publication of a peer-reviewed study…
LaNeo Product Data submitted for a Clinical Trial in CanadaTORONTO, March 26, 2024 (GLOBE NEWSWIRE) -- PharmAla Biotech Holdings Inc.…
TNX-2900 is a proprietary magnesium-potentiated formulation of intranasal oxytocin, a naturally occurring hormone that reduces appetite and eating Prader Willi…
World’s first legal exporters of psilocybin solidifies partnership with acclaimed university in Canada for preclinical studiesRUNAWAY BAY, Jamaica, March 21,…
Four Phase 2 investigator-initiated studies of TNX-1900 (intranasal potentiated oxytocin) are ongoing for pediatric obesity, binge eating disorder, bone health…